Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Tim Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Regional Children's Cystic Fibrosis Centre, Leeds Children's Hospital, Leeds LS1 3EX, United Kingdom. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Cystic Fibrosis, Endpoint Determination, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Imperial Biomedical Research Centre, UK Research and Innovation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Cystic fibrosis is a lifelong progressive disease in which lung disease is the main prognostic factor, where starting early treatment is crucial for improving long-term outcomes. Therefore, new treatment should be available as early as possible. However, choosing appropriate and feasible clinical trial endpoints in children under 2 years of age presents significant challenges. Most studies in this age group have extrapolated pulmonary efficacy from older age groups, focusing on safety, pharmacokinetics, and biomarker response. As lung health is near normal in infants, demonstrating absence of pulmonary decline requires large sample sizes and extended study duration, which may not be feasible for standard regulatory trials. To address this gap, the European Cystic Fibrosis Society Clinical Trials Network developed a consensus document evaluating direct pulmonary endpoints for therapeutic pulmonary studies in this young age group. The pulmonary endpoints evaluated include multiple-breath washout (MBW); chest computed tomography (CT); chest magnetic resonance imaging (MRI); airway infection and inflammation. Relevant literature, pitfalls, practice guidelines, and recommendations are presented. None of the pulmonary endpoints evaluated are currently suitable to serve as a primary efficacy endpoint in children below 2 years of age, as this will require large numbers and long follow-up. For clinical trials in infants with CF, pharmacokinetics, pharmacodynamics, safety and tolerability should remain the primary endpoints, with pulmonary endpoints as secondary or exploratory outcomes. Post authorization studies are essential to evaluate long-term pulmonary benefits, including MBW, structural lung assessment (e.g. CT and MRI), and markers of pulmonary inflammation to fully understand the impact of early therapy initiation in this young population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leeds Regional Children's Cystic Fibrosis Centre, Leeds Children's Hospital, Leeds LS1 3EX, United Kingdom.
- European Cystic Fibrosis Society - Clinical Trial Network, Karup, Denmark; Northern Ireland Clinical Research Facility, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, N Ireland.
- Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Radiology and Nuclear Med…
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Radiology, Policlinico Universitario, Cagliari, Italy.
- UCL Great Ormond Street Institute of Child Health, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
- NHLI, Imperial College, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' Trust, London, UK; ECFS CTN Central Overreading Centre for Lung Clearance Index.
Förderung
- National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
- UK Research and Innovation
Zitieren
APA
Lee, T., Hill, K., Caudri, D., Ciet, P., Davies, G., Davies, J. C., Dittrich, A. M., Lindblad, A., McNally, P., Reix, P., Saunders, C., Sermet-Gaudelus, I., Stahl, M., Tiddens, H. A. W. M., & Janssens, H. M. (2025). Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.06.003
Vancouver
Lee T, Hill K, Caudri D, Ciet P, Davies G, Davies JC, et al. Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.06.003
BibTeX
@article{Lee2025,
author = {Lee, Tim and Hill, Kate and Caudri, Daan and Ciet, Pierluigi and Davies, Gwyneth and Davies, Jane C and Dittrich, Anna-Maria and Lindblad, Anders and McNally, Paul and Reix, Philippe and Saunders, Clare and Sermet-Gaudelus, Isabelle and Stahl, Mirjam and Tiddens, Harm A W M and Janssens, Hettie M},
title = {Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.06.003}
}
EUVIMED